649
Views & Citations10
Likes & Shares
Introduction: Rituximab is
used to treat aggressive and indolent lymphomas and for other autoimmune
diseases. Rituximab usually well endured, however, it is found to be associated
with infusion-related reaction during the first dose mainly. The manufacturer
recommendation is slow initial infusion rate over 3 to 4 h, which requires
healthcare resources and leads to patient dissatisfaction. Researches proved
safety of Rituximab administration over 90 min in subsequent infusions as long
as the first infusion well tolerated with no reaction. Following this protocol
results in more efficient utilization management and treatment practice and
ultimately increase patient satisfaction. This quality improvement project aims
to reduce the Rituximab “Infusion time” considering safety of rapid infusion.
Materials and methods: A total of 50
patients diagnosed with CD20 positive Lymphoma, who were planned to receive
Rituximab, were started infusion over 90 min from the second treatment cycle
and for the later doses once the initial infusion is tolerated well as per the
standard protocol.
Results: Patient
infusion time reduced by 50% with no reaction reported. Accordingly, increased
patient satisfaction rate during the study period.
Conclusion: Rapid
Rituximab infusion rate is safe and accountable for improving the efficiency
that consequently increased patient fulfillment.
Keywords:
Rituximab, Rapid infusion rate, Patient satisfaction, Efficiency
INTRODUCTION
The biological
therapy “Rituximab” is a CD20 antigen targeting monoclonal chimeric immunoglobulin
G1 that is commonly available treatment to manage B-cell lymphoproliferative
disorders [1,2]. Typically, it is being used in conjunction with other
chemotherapy regimens like (CHOP); Cyclophosphamide, Hydroxydaunorubicin,
Oncovin and Prednisone, to treat aggressive as well as indolent lymphomas [2].
It has been proven to improve the disease free survival as well as overall
survival in non-Hodgkin’s lymphoma and chronic B-cell lymphocytic leukemia [3].
Recently it is utilized as a maintenance therapy single-agent used after
response to induction therapy for follicular lymphomas [2] and for other
autoimmune diseases like rheumatoid arthritis [4].
Rituximab is
well endured, however, it is found to be associated with a risk of
infusion-related toxicity, ranging from hypersensitivity reactions, in addition
to cardiovascular/respiratory compromising and distress syndrome [1,2,4], to
death within 24 h [3]. Notwithstanding, the
incidence of infusion
reactions found to reach 77-80%
Ordinarily, the traditional manufacturer
recommendation for Rituximab infusion is to be administered at slow initial
rate over 3 to 4 h that requires an increase in utilized healthcare resources,
decrease in available treatment slots and ultimately leads to patient’s
inconvenience due to lengthy treatment intervals [5]. Several research studies
in a number of countries have been conducted to investigate the feasibility and
safety of an expedited infusion over 60 min and 90 min with a constant or
escalated rate [3,6,7]. Rituximab rapid infusion protocols has been found to be
medically safe when administered during the subsequent infusions after the
first dose been given in a standard routine manner provided it was well
tolerated without any adverse toxicity reaction [1,3,5]. Nevertheless, a lately
published study by Modelevsky et al. [8], confirmed it is medically safe for
patients with primary central nervous system lymphoma (PCNSL). Thereafter,
rapid Rituximab infusion following this converted pharmaceutical protocol is
being used internationally [7,9]. Per se, such policy resulted in a better and
efficient utilization management to healthcare resources [5]. Eventually, this
will lead to reducing the outpatient clinic visits duration and thus the
expectation of elevated patient and healthcare professional satisfaction
[10,11].
MATERIALS AND METHODS
This study was conducted
in an outpatient oncology institute at Johns Hopkins Aramco Healthcare (JHAH);
a large tertiary hospital located in the Kingdom of Saudi Arabia. An ethical
approval was obtained from the Institutional Review Board at JHAH to publish
the data and results of this project. Considering this project as a lean 6
sigma project, we followed DMAIC methodology to accomplish our main goal (DMAIC
is designed to: Determine the problem, Measure the baseline, Analyze the
current situation, Implement the intervention and Check/control the
improvement).
Defining the problem
At the Oncology
Institute of Johns Hopkins Aramco Healthcare (JHAH), the Lymphoma patients who
are (CD20 Positive) receive the Rituximab treatment dose in an average of 3 hours
which is a long infusion time that has been highlighted to lead to patient
dissatisfaction.
Measuring the baseline and analyzing the situation
Data was
collected to calculate the baseline for patients waiting time during Rituximab
infusion process, in order to measure the performance of the existing clinical
practice. The analysis revealed that patients wait for 186 min (3 h) to
complete their chemotherapy infusion and be ready to discharge.
Implementation of action plan
An action plan
was developed based on a comprehensive literature review. Previous clinical
practice at JHAH-oncology indicated that the Rituximab infusion rate given for
the initial infusion was (50 mg/h × 30 min). Efforts of evidence based practice
(EBP) proved that it is safe to increase the first Rituximab infusion dose rate
by 50 mg/h. q30 min, if “No adverse reaction”. Then after, subsequent infusions
rate was increased to (100 mg/h × 30 min) with Max rate of 400 mg/h. The action
plan was applied starting from June 2018. A Rituximab rapid infusion executed
over 90 min from the second treatment cycle. If the initial infusion tolerated
well, a 20% of the dose will be administered over 30 min. Then after, the
remaining 80% is given over 60 min and the same rate will be used for
subsequent doses if tolerated.
Checking/controlling the improvement
Post
implementation of action plan data was collected on November to check
improvement status in the service as well as on Lymphoma patient’s
satisfaction.
RESULTS AND DISCUSSION
Rituximab infusion key performance indicator (KPI)
The average
patients waiting time to Complete Rituximab Infusion was used as a KPI for the
service. According to collected data, analysis revealed a significant reduction
(P ≤ 0.001) in Rituximab infusion time from 186 min to a mean time of 93 min
(95% CI of 91-95) with 50% improvement and time saving (Figure 1).
Oncology patient’s satisfaction rate
The achieved
improvement has sequentially reflected on the patient’s “waiting time at
oncology clinic” satisfaction rate. It was at 78% (during January to May;
pre-implementation of action plan) and enhanced to 85% (during June to October;
post-implementation of action plan) with around 7% improvement. The
satisfaction rate was significantly affected by the implemented change in
Rituximab infusion protocol, as indicated by patient’s comments collected
through the “Press Ganey” survey that is conducted on monthly basis. Moreover,
personal interview with oncology patients who received Rituximab treatment took
place to ensure the level of satisfaction before and after the action plan
implementation (Figure 2).
CONCLUSION
In conclusion, a rapid Rituximab infusion
protocol has demonstrated a safe clinical practice when administered within 90
min during the subsequent doses, with 0% of reaction compared to 10% of the
historical data before implementing the rapid infusion practice. Not only has
this reduced patient treatment times, conversely, this application has led to
sufficient use of the treatment rooms at JHAH oncology institute which
increased the number of served patients during the day. Nevertheless, this has
improved patient satisfaction and the outpatient Oncology Institute’s access to
care results.
However, our next quality initiative is to introduce the Rituximab subcutaneous injection as a simpler, faster and cost effective option. This will further reduce the burden on patients and healthcare providers, as well; it has the potential to dismiss the strains on infusion centers allowing greater patient access to care at oncology institutes.
ACKNOWLEDGEMENT
The authors would like to thank Mr. Ali Abandi from Healthcare Quality Analytic unit at JHAH who provided the needed analytics support.
FINANCIAL SUPPORT AND SPONSORSHIP
The authors disclosed no funding related to
this article.
CONFLICT OF
INTEREST
The authors disclosed
no conflicts of interest related to this article.
1.
Atay S, Barista I, Gundogdu F, Akgedik K, Arpaci A (2012)
Rapid infusion rituximab in lymphoma treatment: 2 year experience in a single
institution. J Oncol Pract 8: 141-143.
2.
Patel J, Ho M, Ho V, Bello C, Djulbegovic B, et al.
(2013) Rapid infusion rituximab for maintenance therapy: Is it feasible? Leuk
Res Treat 2013: 1-4.
3.
Atmar J (2010) Review of the safety and feasibility of
rapid infusion of rituximab. J Oncol Pract 6: 91-93.
4.
Pritchard CH, Greenwald MW, Kremer JM, Gaylis NB, Rigby
W, et al. (2014) Safety of infusing rituximab at a more rapid rate in patients
with rheumatoid arthritis: Results from the RATE-RA study. BMC Musculoskelet
Disord 15: 177.
5.
Monem EA, Al Bahrani B, Mehdi I, Nada A (2014) Rapid
rituximab infusion: Local center experience. Gulf J Oncolog 1: 52-56.
6.
Byrd JC, Murphy T, Howard RS, Lucas MS, Goodrich A, et
al. (2001) Rituximab using a thrice weekly dosing schedule in B-cell chronic
lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical
activity and acceptable toxicity. J Clin Oncol 19: 2153-2164.
7.
Tuthill M, Crook T, Corbet T, King J, Webb A (2009) Rapid
infusion of rituximab over 60 min. Eur J Hematol 82: 322-325.
8.
Modelevsky L, Tizon R, Reiss SN, Smith M, Garonce R, et
al. (2018) Rapid infusion rituximab is well tolerated in patients with primary
CNS lymphoma. CNS Oncol 7: CNS19.
9.
Sehn LH, Donaldson J, Filewich A, Fitzgerald C, Gill KK,
et al. (2007) Rapid infusion rituximab in combination with
corticosteroid-containing chemotherapy or as maintenance therapy is well
tolerated and can safely be delivered in the community setting. Blood 109:
4171-4173.
10.
Swan JT, Zaghloul HA, Cox JE, Murillo JR Jr. (2014) Use
of a pharmacy protocol to convert standard rituximab infusions to rapid
infusion shortens outpatient infusion clinic visits. Pharmacotherapy 34:
686-694.
11.
Dotson E, Crawford B, Phillips G, Jones J (2016)
Sixty-minute infusion rituximab protocol allows for safe and efficient
workflow. Support Care Cancer 24: 1125-1129.
QUICK LINKS
- SUBMIT MANUSCRIPT
- RECOMMEND THE JOURNAL
-
SUBSCRIBE FOR ALERTS
RELATED JOURNALS
- Journal of Ageing and Restorative Medicine (ISSN:2637-7403)
- Journal of Rheumatology Research (ISSN:2641-6999)
- International Journal of Medical and Clinical Imaging (ISSN:2573-1084)
- Advance Research on Alzheimers and Parkinsons Disease
- Journal of Nursing and Occupational Health (ISSN: 2640-0845)
- Journal of Neurosurgery Imaging and Techniques (ISSN:2473-1943)
- Chemotherapy Research Journal (ISSN:2642-0236)